FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
8/10/2022 5:38:58 PM | Chg. +0.0800 | Volume | Bid9:51:58 PM | Ask9:58:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
24.7100EUR | +0.32% | 740 Turnover: 18,314.4000 |
-Bid Size: - | -Ask Size: - | 13.8 bill.EUR | 3.72% | 7.58 |
GlobeNewswire
6/11/2021
UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care
GlobeNewswire
11/11/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
11/4/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/29/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/23/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...
GlobeNewswire
6/9/2017
KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
GlobeNewswire
1/27/2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®